首页|期刊导航|中国临床药理学杂志|精神分裂症患者氨磺必利血药浓度剂量比和高泌乳素血症的影响因素分析

精神分裂症患者氨磺必利血药浓度剂量比和高泌乳素血症的影响因素分析OA

Analysis of influencing factors of concentration/dose ratio and hyperprolactinemia of amisulpride in patients with schizophrenia

中文摘要英文摘要

目的 探讨氨磺必利片稳态血药浓度/剂量比(C/D)和高泌乳素血症(HPRL)的影响因素,为临床合理用药提供参考.方法 将接受氨磺必利片治疗且进行治疗药物监测(TDM)的精神分裂症住院患者纳入为研究对象,收集患者血药浓度结果和相关病历资料,用SPSS 26.0软件进行数据统计及结果分析.结果 共纳入551例患者,氨磺必利片日剂量为600(400,800)mg·d-1,血药浓度为 399.80(260.40,575.80)ng·mL-1,C/D 值为 0.71(0.49,0.95)ng·mL-1·mg-1.女性患者和男性患者的C/D值分别为0.81(0.58,1.06)和0.63(0.43,0.86),在统计学上差异有统计学意义(P<0.05).不同年龄和估算肾小球滤过率(eGFR)患者的C/D值比较,在统计学上差异均无统计学意义(均P>0.05).超重患者、肥胖和偏瘦患者的C/D值分别为0.56(0.41,0.91)、0.64(0.47,0.89)和0.87(0.55,1.13),超重、肥胖患者分别与偏瘦患者比较,在统计学上差异均有统计学意义(均P<0.05).联用氯氮平与不联用氯氮平时,氨磺必利片C/D值分别为0.81(0.57,1.13)和0.67(0.47,0.91),联用阿立哌唑与不联用阿立哌唑时,氨磺必利片C/D值分别为0.83(0.63,1.07)和0.70(0.48,0.93);联用奥氮平与不联用奥氮平时,氨磺必利片C/D值分别为0.59(0.46,0.84)和0.72(0.50,0.97),联用劳拉西泮与联用劳拉西泮时,氨磺必利片C/D值分别为0.61(0.41,0.87)和0.72(0.51,0.96),联用与不联用时比较,氨磺必利片C/D值在统计学上差异均有统计学意义(均P<0.05).195例(97.01%)患者在治疗过程中发生HPRL,多重线性回归分析表明性别和体质量指数(BMI)是HPRL的影响因素(P<0.05).结论 患者的性别、BMI、联合用药(氯氮平、阿立哌唑、奥氮平和劳拉西泮)对氨磺必利C/D值影响显著.另外,女性和低BMI患者使用氨磺必利时需关注泌乳素(PRL)水平.

Objective To investigate the influential factors of the concentration/dose ratio(C/D)and hyperprolactinemia(HPRL)of amisulpride tablets and provide the reference for the rational clinical use of this drug.Methods Schizophrenic inpatients who underwent amisulpride tablets therapeutic drug monitoring(TDM)were included in this study.General information and amisulpride serum concentrations were collected through the medical record system.Data analysis was carried out through the SPSS 26.0 software.Results A total of 551 inpatients were included,the daily dose of amisulpride tablet was 600(400,800)mg·d-1,serum concentration was 399.80(260.40,575.80)ng·mL-1 and C/D was 0.71(0.49,0.95)ng·mL-1·mg-1.The C/D ratios of amisulpride tablets among women and men were 0.81(0.58,1.06)and 0.63(0.43,0.86),with statistically significant differences(P<0.05).Age and estimated glomerular filtration rate(eGFR)level both did not affect the C/D ratio of amisulpride,with no statistically significant differences(all P>0.05).The C/D ratio of overweight,obese group and underweight group were 0.56(0.41,0.91),0.64(0.47,0.89)and 0.87(0.55,1.13),respectively,with statistically significant difference when compared overweight,obese group with underweight group(all P<0.05).The C/D ratios of amisulpride tablets in patients with and without clozapine use were 0.81(0.57,1.13)and 0.67(0.47,0.91),respectively;the C/D ratios in patients with and without aripiprazole use were 0.83(0.63,1.07)and 0.70(0.48,0.93),respectively;the C/D ratios in patients with and without olanzapine use were 0.59(0.46,0.84)and 0.72(0.50,0.97),respectively;and the C/D ratios of amisulpride tablets in patients with and without lorazepam use were 0.61(0.41,0.87)and 0.72(0.51,0.96),respectively.The differences in the C/D ratios of amisulpride tablets between the use and non-use groups were statistically significant in all cases(all P<0.05).195 patients(97.01%)had HPRL after medication,multiple linear regression analysis indicated that gender and body mass index(BMI)all statistically significantly influenced HPRL(all P<0.05).Conclusion The C/D ratios of amisulpride are affected by gender,BMI,clozapine comedication,aripiprazole comedication,olanzapine comedication and lorazepam comedication.In addition,woman and underweight patients need pay more attention to PRL level after medication.

王裕锋;彭陈陈;张茉莉;蒋家兵;曾环思

深圳市精神卫生中心/深圳市康宁医院 生化与药学实验室,广东 深圳 518118深圳市精神卫生中心/深圳市康宁医院 生化与药学实验室,广东 深圳 518118深圳市精神卫生中心/深圳市康宁医院 药学部,广东 深圳 518118深圳市精神卫生中心/深圳市康宁医院 生化与药学实验室,广东 深圳 518118深圳市精神卫生中心/深圳市康宁医院 生化与药学实验室,广东 深圳 518118

医药卫生

氨磺必利片治疗药物监测血药浓度剂量比治疗参考范围高泌乳素血症

amisulpride tablettherapeutic drug monitoringconcentration/dose ratiotherapeutic reference rangehyperprolactinemia

《中国临床药理学杂志》 2026 (14)

1985-1991,7

广东省高水平临床重点专科(深圳市配套建设经费)资助项目(SZGSP013)

10.13699/j.cnki.1001-6821.2026.14.006

评论